SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Diagnocure CUR
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cal Gary who wrote (130)2/20/2002 5:53:45 PM
From: Mr. L. Neufeldt  Read Replies (1) of 132
 
The PCA3 technology has such potential.
uPM3 has come back with great sensitivity but the specificity is lower than their first initial testing of a smaller group of samples. The specificity is really not much better than PSA. Clinically better but is it significant enough? They're saying in their news release that the first test done had "substantial number of urine samples from normal men that created higher average specificity values" I guess we'll have to wait and see if they can improve the results for FDA.
The other positive is that the results should have improve significantly when in combination with the PSA test. As the uPM3 is not a stand alone test but a complimentary test to PSA. These results in combination were not released. I trust they'll be released at the upcoming urology meeting. If this is the case than the uPM3 is ready to go to market as is and we should see a major pharma come in after the urology meetings. Time will tell!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News